KSI-501 in wAMD: The ongoing Phase 3 DAYBREAK study is designed to evaluate immediacy and differentiated efficacy Topline data Sept. 2026 Noninferiority Phase 3 DAYBREAK Objective: Explore efficacy potential of bispecific IL-6 and VEGF inhibition 42 Differentiated efficacy exploration High-need patients Treats until dry, enables monthly dosing and detects disease reactivation earlier Long-durability patients Allows patients without active disease to safely go to every 6-month dosing Primary Endpoint End of Study AI-based tool precisely measures fluid in the eye to optimize treatment per patient at each individualized treatment visit (after loading doses)